Monograph Details
|
|
Dermatological Disorders
> Miscellaneous dermatological conditions
|
|
TRI-LUMA |
| Manufacturer |
|
Galderma Laboratories, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Skin depigmenting agent + topical steroid + retinoid. |
| Generic Name |
|
Hydroquinone 4%, fluocinolone acetonide 0.01%, tretinoin 0.05%; crm; contains sulfites, parabens. |
| Indications |
|
Short-term intermittent treatment of moderate to severe melasma of the face, with measures for sun avoidance including sunscreen use (SPF 30). |
| Children |
|
Not recommended. |
| Adults |
|
Clean (use a mild, soap-free cleanser) and dry skin. Apply a thin film to affected area(s) and to 1/2 inch of surrounding normal skin once daily, at least 30 minutes before bedtime. |
| Precautions |
|
Do not occlude or use on eczema or sunburned skin. Avoid eyes, ears, mouth, angle of nose, mucous membranes, sun, UV light. Skin types V and VI (possible undesirable excessive bleaching). Discontinue if ochronosis, chemical irritation, hypersensitivity, or HPA axis suppression occurs. Increased irritation in extreme weather. Elderly. Pregnancy (Cat.C), nursing mothers: consider delaying use until after pregnancy/nursing. |
| Interactions |
|
Avoid photosensitizers, topical irritants, and drying agents. |
| Adverse Reactions |
|
Local irritation (erythema, peeling, burning, dryness, pruritus), acne, paresthesia, telangiectasia, hyperesthesia, folliculitis, dermatitis, secondary infection, hypertrichosis, skin atrophy, striae, miliaria, HPA axis suppression. |
| How Supplied |
|
Crm—30g |
|
|
|
|
